Research on apolipoprotein e (APOE) is being explored as a potential target for therapeutics to treat alzheimer's disease. Studies in mice have shown that switching the APOE4 allele to APOE2 can improve metabolic signatures, neuropathology, and cognition related to the disease. Various organizations are working on developing treatments, including oral drugs, with some showing promise and safety in early tests.